RxDoctor Payments Data

Clara Cabrera, MD

Internal Medicine · Stoneham, MANPI 1487851697

Payments from drug & device makers

$4,120in general payments, 2019–2025

Across 124 payments — averaging $33.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$716
  • Novo Nordisk$288
  • E.r. Squibb & Sons, L.L.C.$245
  • Pfizer$233
  • Merck$168
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$4,120100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,120 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$175,088
Medicare patients
335
Services billed
1,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$100,200
TrulicityDulaglutide38$70,631
Synjardy XrEmpagliflozin/Metformin Hcl56$57,080
Diclofenac Sodium36$26,329
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$19,665
JanumetSitagliptin Phos/Metformin Hcl11$17,755
LinzessLinaclotide19$16,231
FarxigaDapagliflozin Propanediol12$15,307
Breo ElliptaFluticasone/Vilanterol17$6,740
Atorvastatin Calcium367$6,601
Xigduo XrDapaglifloz Propaned/Metformin12$6,599
Incruse ElliptaUmeclidinium Bromide19$6,212
Rosuvastatin Calcium252$6,054
Valsartan84$5,338
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$4,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$233$100,200100 claims
Lilly USA, LLCTrulicity$165$70,63138 claims
Boehringer IngelheimSynjardy Xr$77$57,08056 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$1,208$32,61763 claims
AbbVieLinzess, Synthroid$76$17,95857 claims
MerckJanumet$168$17,75511 claims
AstraZenecaFarxiga$716$15,30712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Stoneham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →